TL;DR: The Centers for Medicare & Medicaid Services modified NCD 378, its coverage policy for implantable pulmonary artery pressure sensors (IPAPS) for heart failure management, effective January 9, 2026. Here's what changes for billing teams.
This update establishes Coverage with Evidence Development (CED) as the framework for Medicare coverage of IPAPS devices used in heart failure management. The policy does not list specific CPT or HCPCS codes, so your billing team needs to identify the applicable codes through your MAC and coordinate with your compliance officer before submitting claims under this coverage. The stakes are high — IPAPS implantation and ongoing monitoring generate significant reimbursement exposure, and the patient qualification criteria are tightly defined.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Implantable Pulmonary Artery Pressure Sensors for Heart Failure Management |
| Policy Code | NCD 378 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | High |
| Specialties Affected | Cardiology, Cardiac Electrophysiology, Interventional Cardiology, Heart Failure Programs, Inpatient and Outpatient Hospital Billing |
| Key Action | Confirm your HF patients meet all seven patient criteria and that your CED study enrollment is active before submitting claims after January 9, 2026 |
CMS Implantable Pulmonary Artery Pressure Sensor Coverage Criteria and Medical Necessity Requirements 2026
NCD 378 is the National Coverage Determination governing Medicare coverage of implantable pulmonary artery pressure sensors for heart failure management. Under this modified coverage policy, CMS covers IPAPS exclusively under Coverage with Evidence Development — meaning coverage is tied to enrollment and participation in a CMS-approved CED study. If your patient isn't enrolled in an approved study, there is no Medicare coverage. Full stop.
This is the central billing reality of NCD 378. CED coverage is not a formality. It's a hard condition of reimbursement, and it changes how your intake process, documentation workflow, and claim submission must work.
Patient Eligibility Criteria
Medical necessity under this coverage policy depends on seven patient-level conditions. All seven must be met. Miss one and you don't have a covered service.
1. Chronic heart failure diagnosis. The patient must have a diagnosis of chronic HF lasting at least three months. They must also be in New York Heart Association (NYHA) functional Class II or III within the past 30 days before IPAPS implantation. This applies regardless of left ventricular ejection fraction (LVEF) — which is a meaningful broadening compared to some prior device coverage standards.
2. Recent HF hospitalization or elevated natriuretic peptides. The patient must have had an HF hospitalization or an urgent HF visit — defined as an ER or outpatient visit requiring intravenous diuretic therapy — within the past 12 months. Alternatively, elevated natriuretic peptides within the past 30 days satisfies this criterion.
3. Guideline-directed medical therapy. The patient must be on GDMT for at least three months before implantation, with the goal of achieving optimal or maximally-tolerated therapy. Document this thoroughly. Gaps in GDMT history are a fast path to claim denial.
4. ICD or CRT evaluation. The patient must have been evaluated for — and received if appropriate — an implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy pacemaker (CRT-P), or CRT-Defibrillator (CRT-D). If a device was implanted, that implantation must have occurred at least three months before IPAPS implantation.
5. No recent major cardiovascular event. The patient cannot have experienced a major cardiovascular event — including unstable angina, myocardial infarction, percutaneous coronary intervention, open heart surgery, or stroke — within three months before IPAPS implantation.
6. Reliable connectivity. The patient must have access to reliable connectivity. The IPAPS external data gathering unit sends daily pulmonary artery pressure trends from the patient's home to their physician. No connectivity, no data transmission. No data transmission, no coverage under this framework.
7. No implantation during acute HF hospitalization. IPAPS implantation cannot occur during a hospital admission for an acute HF episode. If a patient is admitted for decompensated heart failure, the implant must wait.
Physician Criteria
Medical necessity documentation also requires the right practitioners. Cardiologists with training and experience in heart failure management must handle referrals and post-implantation management. The implanting physician must have training and experience in pulmonary arterial catheterization and intervention. These aren't soft recommendations — they're coverage criteria. Document physician credentials in the record.
CED Study Requirements
This is where the coverage policy gets operationally complex. Every IPAPS service must be furnished through a CMS-approved CED study. The study protocol must include only patients meeting the criteria above, must use only qualified practitioners, and must meet specific data collection and reporting requirements. If your facility isn't actively participating in an approved CED study, you can't bill for these services under NCD 378 — regardless of how well your patient meets the clinical criteria.
Talk to your compliance officer before the effective date if you're not certain your CED study enrollment is current and active.
CMS IPAPS Exclusions and Non-Covered Indications
The CED framework itself defines the primary exclusion: IPAPS services furnished outside of a CMS-approved CED study are not covered. This applies even when the patient meets every clinical criterion in section B.1.
Implantation during a hospital admission for acute decompensated heart failure is explicitly excluded. The timing matters and is a hard stop, not a documentation issue.
Patients who do not meet all seven eligibility conditions are not covered. CMS doesn't provide a coverage pathway for patients who partially qualify. There's no "close enough" here.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| IPAPS implantation for chronic HF, NYHA Class II or III, meeting all patient criteria, enrolled in CMS-approved CED study | Covered | Not specified in NCD 378 — confirm with your MAC | All seven patient criteria must be met; CED enrollment required |
| IPAPS management and monitoring post-implantation by qualified cardiologist | Covered | Not specified in NCD 378 — confirm with your MAC | Referring/managing physician must be HF-trained cardiologist |
| IPAPS implantation during acute HF hospitalization | Not Covered | N/A | Explicitly excluded regardless of patient eligibility |
| IPAPS services furnished outside a CMS-approved CED study | Not Covered | N/A | No CED enrollment = no coverage under NCD 378 |
| IPAPS for patients who do not meet all seven patient eligibility criteria | Not Covered | N/A | Partial eligibility is not sufficient |
| IPAPS implantation without prior ICD/CRT evaluation (where applicable) | Not Covered | N/A | Evaluation — and device implantation at least 3 months prior, if appropriate — is a coverage requirement |
CMS Implantable Pulmonary Artery Pressure Sensor Billing Guidelines and Action Items 2026
The complexity of NCD 378 creates real operational risk for billing teams. Here's what to do before and after January 9, 2026.
| # | Action Item |
|---|---|
| 1 | Confirm your CED study status immediately. If your facility implants or manages IPAPS devices, verify right now that you're enrolled in a CMS-approved CED study. This isn't optional — it's the foundation of every covered claim under this policy. If you're not enrolled, work with your physician leadership and compliance officer to identify an approved study before you bill for any service. |
| 2 | Build a seven-point patient eligibility checklist into your pre-implant workflow. Every patient must clear all seven criteria before implantation. Create a structured checklist — NYHA classification within 30 days, three-month GDMT history, hospitalization or natriuretic peptide documentation within the required windows, ICD/CRT evaluation with timing, no major cardiovascular event in the prior three months, connectivity access confirmation, and confirmation that the patient is not currently admitted for acute HF. This checklist becomes your medical necessity documentation. |
| 3 | Document physician credentials in every patient record. The referring and managing cardiologist's HF training and experience must be in the record. The implanting physician's pulmonary arterial catheterization credentials must also be documented. Insurers reviewing claims under CED policies scrutinize practitioner qualifications — don't leave this to assumption. |
| 4 | Clarify applicable CPT and HCPCS codes with your Medicare Administrative Contractor. NCD 378 does not list specific billing codes. This is a known gap in the policy and a practical problem for pulmonary artery pressure sensor billing. Contact your MAC now to confirm which codes apply to IPAPS implantation, device management, and data monitoring services. Don't wait until you have a claim in queue. |
| 5 | Review your prior authorization process for IPAPS services. Although NCD 378 does not specify prior authorization requirements explicitly, CED-linked coverage policies often have prior auth touchpoints built into the approved study protocol. Confirm with your study coordinator and your MAC whether prior authorization is required for implantation or ongoing monitoring services. |
| 6 | Audit your connectivity documentation. The patient's reliable connectivity is a coverage criterion — not a clinical nice-to-have. Your intake process should capture and document connectivity access before implantation is scheduled. A claim denial based on undocumented connectivity is avoidable. |
| 7 | Coordinate with your compliance officer on CED study reporting obligations. CED coverage links reimbursement to data collection. If your facility isn't meeting the CED study's reporting requirements, coverage can be challenged retroactively. Make sure your billing team understands the study's data submission obligations — and who owns them operationally. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Implantable Pulmonary Artery Pressure Sensors Under NCD 378
No Codes Listed in NCD 378
NCD 378 as modified effective January 9, 2026 does not specify CPT, HCPCS Level II, or ICD-10-CM codes. This is a material gap in the policy. Implantable pulmonary artery pressure sensor billing requires code-level clarity before you can submit claims, and CMS hasn't provided it here.
Your immediate action: contact your MAC directly to confirm which codes apply to IPAPS implantation, post-implantation physician management, and remote data monitoring services under this NCD. Different MACs sometimes map procedures differently when the NCD is silent on codes, and a mismatch between your billed code and what your MAC expects will trigger a claim denial.
Until your MAC confirms applicable codes, do not bill IPAPS-related services and assume coverage. The absence of codes in the policy document does not create a billing pathway — it creates a gap you need to close through direct MAC inquiry.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.